CA1303995C - EFFET D'UNE COMBINAISON D'UN AGONISTE .beta.- ADRENERGIQUE ET DE CERTAINS INHIBITEURS DES RECEPTEURS H _ET/OU H _DE L'HISTAMINE SUR LES LESIONS GASTRO-INTESTINALES PRODUITES PAR DES COMPOSITIONS ANTI-INFLAMMATOIRES NON STEROIDIENNES - Google Patents

EFFET D'UNE COMBINAISON D'UN AGONISTE .beta.- ADRENERGIQUE ET DE CERTAINS INHIBITEURS DES RECEPTEURS H _ET/OU H _DE L'HISTAMINE SUR LES LESIONS GASTRO-INTESTINALES PRODUITES PAR DES COMPOSITIONS ANTI-INFLAMMATOIRES NON STEROIDIENNES

Info

Publication number: CA1303995C
Authority: CA; Canada
Prior art keywords: day; histamine; beta; receptor; nonsteroidal anti
Prior art date: 1986-08-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA000537615A

Other languages

English (en)

Inventor

Joseph J. Piala

Alison B. Lukacsko

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Co

Original Assignee

Bristol Myers Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-08

Filing date

1987-05-21

Publication date

1992-06-23

1987-05-21 Application filed by Bristol Myers Co filed Critical Bristol Myers Co

1992-06-23 Application granted granted Critical

1992-06-23 Publication of CA1303995C publication Critical patent/CA1303995C/fr

2009-06-23 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000808 adrenergic beta-agonist Substances 0.000 title claims abstract description 29
239000000203 mixture Substances 0.000 title claims description 41
206010061172 Gastrointestinal injury Diseases 0.000 title claims description 12
230000003110 anti-inflammatory effect Effects 0.000 title claims description 11
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title description 30
229960001340 histamine Drugs 0.000 title description 15
230000000694 effects Effects 0.000 title description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 34
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 34
229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims abstract description 27
108090000110 Histamine H1 Receptors Proteins 0.000 claims abstract description 9
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 18
229960001138 acetylsalicylic acid Drugs 0.000 claims description 18
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical group CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 16
229960000195 terbutaline Drugs 0.000 claims description 16
239000003485 histamine H2 receptor antagonist Substances 0.000 claims description 14
239000004615 ingredient Substances 0.000 claims description 12
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical group [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 10
229960000620 ranitidine Drugs 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 9
230000000903 blocking effect Effects 0.000 claims description 8
229960000520 diphenhydramine Drugs 0.000 claims description 8
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 8
239000002552 dosage form Substances 0.000 claims description 8
102000000543 Histamine Receptors Human genes 0.000 claims description 6
108010002059 Histamine Receptors Proteins 0.000 claims description 6
239000000938 histamine H1 antagonist Substances 0.000 claims description 6
102000005962 receptors Human genes 0.000 claims description 5
108020003175 receptors Proteins 0.000 claims description 5
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 4
229960001680 ibuprofen Drugs 0.000 claims description 4
102000003834 Histamine H1 Receptors Human genes 0.000 claims description 3
102000003710 Histamine H2 Receptors Human genes 0.000 claims description 3
108090000050 Histamine H2 Receptors Proteins 0.000 claims description 3
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
229960002009 naproxen Drugs 0.000 claims description 3
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
230000001681 protective effect Effects 0.000 claims description 3
230000002829 reductive effect Effects 0.000 claims description 3
239000000048 adrenergic agonist Substances 0.000 claims description 2
239000002260 anti-inflammatory agent Substances 0.000 claims 2
229940121363 anti-inflammatory agent Drugs 0.000 claims 2
230000002178 gastroprotective effect Effects 0.000 claims 2
230000003389 potentiating effect Effects 0.000 claims 2
230000006378 damage Effects 0.000 abstract description 8
208000027418 Wounds and injury Diseases 0.000 abstract description 7
208000014674 injury Diseases 0.000 abstract description 7
238000000034 method Methods 0.000 abstract description 2
210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229940085339 aspirin 975 mg Drugs 0.000 description 22
241000282472 Canis lupus familiaris Species 0.000 description 15
238000012360 testing method Methods 0.000 description 12
239000003814 drug Substances 0.000 description 7
230000002496 gastric effect Effects 0.000 description 7
210000002784 stomach Anatomy 0.000 description 7
JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 5
229960001140 cyproheptadine Drugs 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003087 receptor blocking agent Substances 0.000 description 5
239000000739 antihistaminic agent Substances 0.000 description 4
230000003902 lesion Effects 0.000 description 4
-1 maleate salt Chemical class 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
239000000556 agonist Substances 0.000 description 3
230000000740 bleeding effect Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000007794 irritation Effects 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
239000003826 tablet Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
206010053155 Epigastric discomfort Diseases 0.000 description 2
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
101150056637 Hrh2 gene Proteins 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
206010037549 Purpura Diseases 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
208000030304 gastrointestinal bleeding Diseases 0.000 description 2
150000003840 hydrochlorides Chemical class 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
206010034754 petechiae Diseases 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
XCIDNCPEXLYEOP-UHFFFAOYSA-N 2-oxo-1h-pyrazine-3-carbaldehyde Chemical class OC1=NC=CN=C1C=O XCIDNCPEXLYEOP-UHFFFAOYSA-N 0.000 description 1
PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010037867 Rash macular Diseases 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
QGLZXHRNAYXIBU-WEVVVXLNSA-N aldicarb Chemical compound CNC(=O)O\N=C\C(C)(C)SC QGLZXHRNAYXIBU-WEVVVXLNSA-N 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
229940111136 antiinflammatory and antirheumatic drug fenamates Drugs 0.000 description 1
229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229940054051 antipsychotic indole derivative Drugs 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
239000003434 antitussive agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
229960000725 brompheniramine Drugs 0.000 description 1
239000007894 caplet Substances 0.000 description 1
OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
229960000428 carbinoxamine Drugs 0.000 description 1
229960003291 chlorphenamine Drugs 0.000 description 1
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
229960003564 cyclizine Drugs 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
150000002169 ethanolamines Chemical class 0.000 description 1
150000002171 ethylene diamines Chemical class 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
230000003419 expectorant effect Effects 0.000 description 1
229940066493 expectorants Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
229960001596 famotidine Drugs 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
229960000930 hydroxyzine Drugs 0.000 description 1
150000002475 indoles Chemical class 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229940039009 isoproterenol Drugs 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
229960003464 mefenamic acid Drugs 0.000 description 1
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
229960002657 orciprenaline Drugs 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000001139 pH measurement Methods 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960002895 phenylbutazone Drugs 0.000 description 1
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
150000004885 piperazines Chemical class 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
150000003873 salicylate salts Chemical class 0.000 description 1
229940125706 skeletal muscle relaxant agent Drugs 0.000 description 1
239000000050 smooth muscle relaxant Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000000243 solution Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960001017 tolmetin Drugs 0.000 description 1
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
238000012549 training Methods 0.000 description 1
229960003223 tripelennamine Drugs 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000537615A 1986-08-08 1987-05-21 EFFET D'UNE COMBINAISON D'UN AGONISTE .beta.- ADRENERGIQUE ET DE CERTAINS INHIBITEURS DES RECEPTEURS H _ET/OU H _DE L'HISTAMINE SUR LES LESIONS GASTRO-INTESTINALES PRODUITES PAR DES COMPOSITIONS ANTI-INFLAMMATOIRES NON STEROIDIENNES Expired - Fee Related CA1303995C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89498286A	1986-08-08	1986-08-08
US894,982		1986-08-08

Publications (1)

Publication Number	Publication Date
CA1303995C true CA1303995C (fr)	1992-06-23

Family

ID=25403781

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000537615A Expired - Fee Related CA1303995C (fr)	1986-08-08	1987-05-21	EFFET D'UNE COMBINAISON D'UN AGONISTE .beta.- ADRENERGIQUE ET DE CERTAINS INHIBITEURS DES RECEPTEURS H _ET/OU H _DE L'HISTAMINE SUR LES LESIONS GASTRO-INTESTINALES PRODUITES PAR DES COMPOSITIONS ANTI-INFLAMMATOIRES NON STEROIDIENNES

Country Status (1)

Country	Link
CA (1)	CA1303995C (fr)

1987
- 1987-05-21 CA CA000537615A patent/CA1303995C/fr not_active Expired - Fee Related

Legal Events

Date	Code	Title	Description
2004-06-23	MKLA	Lapsed

Publication	Publication Date	Title
US4757060A (en)	1988-07-12	Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
US5037815A (en)	1991-08-06	Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers
US4965065A (en)	1990-10-23	Gastroprotective process and compositions
AU606638B2 (en)	1991-02-14	Nonsteroidal anti-inflammatory drug composition containing h1 blockers, h2 blockers, beta-adrenergic agonists or combinations thereof and an alkalizing agent, and process for administration
JPS61151125A (ja)	1986-07-09	ジヒドロコデイン／イブプロフエン薬剤組成物及び方法
EP0140921A1 (fr)	1985-05-15	Compositions pharmaceutiques.
AP324A (en)	1994-03-07	Medicaments for treating inflammatory conditions or for analgiesia.
US5260333A (en)	1993-11-09	Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
BG63329B1 (bg)	2001-10-31	Лекарствени форми, съдържащи ибупрофен и кодеин
US20120064152A1 (en)	2012-03-15	Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same
US5037823A (en)	1991-08-06	Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
US5043358A (en)	1991-08-27	Gastroprotective process
US5071842A (en)	1991-12-10	Aspirin-containing composition including diphenhydramine and an alkalizing agent to reduce gastrointestinal injury potential
JP5542309B2 (ja)	2014-07-09	経口医薬組成物
AU601007B2 (en)	1990-08-30	The effect of a combination of a beta-adrenergic agonist and certain histamine h1-and/or h2-receptor blockers on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
US20020169212A1 (en)	2002-11-14	Ketoprofen powder for oral use
JPH05509293A (ja)	1993-12-22	不整脈および発作の治療における５―ｈｔ４受容体拮抗剤の使用
JPH05221857A (ja)	1993-08-31	配合解熱鎮痛剤
CA1300507C (fr)	1992-05-12	Composition de medicament non steroidique anti-inflammatoire contenant des agents bloquants h _et h , des antagonistes beta-adrenergiques ou une combinaison de ceux-ci, et procedepour leur administration
JP2586922B2 (ja)	1997-03-05	ある種のｈ▲下１▼およびｈ▲下２▼受容体遮断剤の組合せにより消化管損傷に対して保護された非ステロイド系抗炎症組成物
CZ79593A3 (en)	1994-01-19	Antitussive preparation
JP2000095707A (ja)	2000-04-04	苦味を有する薬物を含有する口中溶解型又は咀嚼型固形内服医薬組成物
JPH01197443A (ja)	1989-08-09	Ｈ↓１ブロッカー、ｈ↓２ブロッカー、ベーターアドレナリン作用剤又はそれらの組み合せ及びアルカリ化剤を含む非ステロイド抗炎症薬剤組成物及び投与方法
JPH01197444A (ja)	1989-08-09	非ステロイド系抗炎症組成物によって生じる消化管損傷に対するβ−アドレナリン作用薬とある種のヒスタミンＨ↓１−および／またはＨ↓２−受容体遮断薬との組合せの効果
US3074848A (en)	1963-01-22	2-hydroxy-5,2'-dichloro-4'-nitrobenzanilide for combating tapeworms